Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ludwig Cancer Research announced today the appointment of Sebastian Nijman as Associate Member of its Oxford Branch. Nijman joins the Ludwig Institute for Cancer Research Oxford after several years as a principal investigator at the prestigious Research Center for Molecular Medicine of the Austrian Academy of Sciences, where he has developed cutting-edge technologies to explore the molecular interactions by which drugs - and drug candidates - exert their effects within cells. His aim is to apply such novel pharmacogenomic technologies to improve the use of existing cancer drugs and to develop novel therapies, with a special emphasis on breast and lung cancers.